Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.

Journal of pharmacokinetics and pharmacodynamics - 1 Dec 2015

Haseltine Eric L, Kimko Holly, Luo Haobin, Tolsma John, Bartels Doug J, Kieffer Tara L, Garg Varun

Abstract excerpt

Viral dynamic modelling has proven useful for designing clinical studies and predicting treatment outcomes for patients infected with the hepatitis C virus. Generally these models aim to capture and predict the on-treatment viral load dynamics from a small study of individual patients. Here, we explored extending these models (1) to clinical studies with numerous patients and (2) by incorporating additional data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Drug Therapy, Combination

Share to Interferon-alpha

Share to Nonlinear Dynamics

Share to Oligopeptides

Share to Ribavirin

Source

Identifiers

PMID: 26289844
DOI: 10.1007/s10928-015-9435-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies.PMID 26289844Read ↗

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.Semantic proximity Read ↗

Rapid emergence of protease inhibitor resistance in hepatitis C virus.Semantic proximity Read ↗

Rational design and adaptive management of combination therapies for Hepatitis C virus infectionSemantic proximity Read ↗

Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.Semantic proximity Read ↗

A perspective on modelling hepatitis C virus infectionSemantic proximity Read ↗

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.Semantic proximity Read ↗

Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.Semantic proximity Read ↗

Modelling the elimination of hepatitis C virus infection as a public health threatSemantic proximity Read ↗

Modelling hepatitis C therapy—predicting effects of treatmentSemantic proximity Read ↗

Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.Semantic proximity Read ↗

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.Semantic proximity Read ↗

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.